FDA agrees to key aspects of pivotal trial design for zervimesine

Cognition Therapeutics received FDA feedback agreeing that DLB psychosis is an approvable outcome and aligning on its Phase 3 trial design. This regulatory milestone paves the way for the first durable treatment for the condition, potentially replacing dangerous off-label antipsychotics.